Overview

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the activity of Brentuximab vedotin in refractory germ cell tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione Michelangelo
Collaborators:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Millennium Pharmaceuticals, Inc.
Treatments:
Antibodies, Monoclonal
Brentuximab Vedotin